Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNK333 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| DNK333 5 mg | EXPERIMENTAL | - |
| Placebo to DNK333 5mg | PLACEBO_COMPARATOR | - |
| DNK333 25 mg | EXPERIMENTAL | - |
| Placebo to DNK333 25 mg | PLACEBO_COMPARATOR | - |
| DNK333 100 mg | EXPERIMENTAL | - |
| Placebo to DNK333 100 mg | PLACEBO_COMPARATOR | - |
| Betamethasone 4 mg | ACTIVE_COMPARATOR | - |
| DNK333 1 mg | EXPERIMENTAL | - |
| placebo 1mg | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNK333 5 mg | DRUG | 5 mg oral |
| Placebo to 5 mg | DRUG | 5 mg placebo oral |
| DNK333 25 mg | DRUG | 25 mg oral |
| Placebo to 25 mg | DRUG | 25 mg placebo oral |
| DNK333 100 mg | DRUG | 100 mg oral |
| Placebo to 100 mg | DRUG | 100 mg placebo oral |
| Betamethasone 4 mg | DRUG | 4 mg oral |
| DNK333 1mg | DRUG | 1 mg oral |
| Placebo to 1mg | DRUG | 1 mg placebo oral |
| DNK333 | DRUG | DNK333 25mg b.i.d. given orally for 4 weeks |
| Placebo | DRUG | Matching placebo |
Inclusion Criteria: * Male and female atopic dermatitis patients,18 to 60 years of age inclusive, who fulfill the following criteria: * Requirement of systemic therapy * Itch VAS score higher than 50 mm * EASI score higher than 8 Exclusion Criteria: * Women of child-bearing potential who are not ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
DNK333 is an investigational small molecule being studied for irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome, and pruritus in patients with atopic dermatitis. It is being developed by Novartis AG (NVS) and is currently in Phase 2 clinical development.
DNK333 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for gastrointestinal and dermatological indications.
DNK333 is in Phase 2 clinical development. It has completed three Phase 2 trials, including studies in women with diarrhea-predominant irritable bowel syndrome and in patients with atopic dermatitis-related pruritus. The drug is investigational and has not been approved by regulatory authorities.
DNK333 has completed three Phase 2 clinical trials: NCT00394173 and NCT00699166 in women with diarrhea-predominant irritable bowel syndrome, and NCT01033097 in patients with pruritus associated with atopic dermatitis. These trials were conducted in the United States, Canada, and Germany.
DNK333 is the primary name for this investigational compound. No alternative names have been reported in the clinical trial data. The drug is being studied under this identifier across all its Phase 2 trials for irritable bowel syndrome and atopic dermatitis-related pruritus.